Angharad de Cates still remembers the first participant who, after days of cognitive testing, looked up and said, "I feel sharper—like my thoughts aren’t stuck in mud anymore." That moment, small but profound, came during a groundbreaking trial at the University of Birmingham, where a common laxative is showing unexpected promise in lifting the mental haze that lingers long after depression’s worst symptoms fade. For millions who battle what’s colloquially known as “brain fog”—a fog that clouds memory, slows thinking, and erodes focus—this research could mark a turning point.
Cognitive dysfunction is one of the most persistent and disabling aspects of depression, often outlasting mood symptoms and undermining work, relationships, and recovery. Yet, treatments have largely ignored this dimension—until now. Dr. de Cates and a team from the University of Oxford have published results in Psychological Medicine showing that prucalopride, a drug approved for chronic constipation, significantly improved cognitive performance in people with a history of depression. The trial included 50 adults aged 18 to 40, all of whom had experienced at least two depressive episodes but were currently symptom-free and not on medication. Half received 2 mg of prucalopride daily for five to eight days after titration—the standard dose for constipation—while the other half received a placebo.
Before and after treatment, participants completed a battery of cognitive tests: the Auditory Verbal Learning Test (AVLT) for memory, the N-back for working memory, and the Trail Making Test (TMT) and Digit Symbol Substitution Test (DSST) for attention and processing speed. The results were striking. Those on prucalopride showed not only greater accuracy (z = +0.59) but also faster response times (z = -0.69) across the board. Crucially, no serious side effects were reported—participants didn’t experience disruptive bowel movements, thanks to the drug’s gentle, targeted action on serotonin 5-HT4 receptors in both the gut and brain.
This dual action may be the key. By stimulating 5-HT4 receptors, prucalopride appears to enhance neural plasticity and neurotransmitter activity linked to learning and memory. “Cognitive problems, or brain fog, are an important and often overlooked feature of depression, and can persist even when mood improves,” said Dr. de Cates. The implications extend beyond depression: earlier studies suggest 5-HT4 agonists may also reduce the risk of developing depression in the first place.
Funded by the NIHR Biomedical Research Centre: Oxford Health, the study is a proof of concept—one that opens a new frontier in mental health treatment. As Professor Susannah Murphy of Oxford, senior author of the study, put it, “This study provides early evidence that 5-HT4 receptor agonists could help restore aspects of cognitive function, opening an exciting new direction for treatment development.” With further trials underway, the hope is that a drug already trusted for digestive health could become a quiet revolution in mental clarity.